These five TNF-blocking agents are currently licensed for the treatment of a variety of disorders, namely, RA (INX, ETP, ADB, CZP, and GLB), juvenile idiopathic arthritis (JIA) (ETP and ADB), ankylosing spondylitis (AS) (INX, ETP, ADB, and GLB), psoriasis (INX, ETP, and ADB), psoriatic arthritis (PsA) (INX, ETP, ADB, and GLB), Crohn's disease (CD) (INX, ADB, and CZP) and ulcerative colitis (UC) (INX and ADB) [3–5, 7–9]. This evidence concerns the gene TNF and juvenile idiopathic arthritis.